Objective: To determine whether opportunistic salpingectomy in patients undergoing laparoscopic myomectomy has any deleterious effects on ovarian reserve and surgical risk. Study Design: We performed a retrospective review of patients who had no desire for future child bearing and who were undergoing laparoscopic myomectomy for symptomatic myomas at 4 institutions. Among them, 41 patients concurrently underwent opportunistic salpingectomy (the opportunistic salpingectomy group) and 65 patients did not undergo salpingectomy at the time of laparoscopic myomectomy (the no-salpingectomy group). The primary and secondary outcome measures were change of ovarian reserve determined by the rate of decline in the anti-Müllerian hormone (AMH) level from before surgery to 3 months post-surgery, and surgical outcomes. Results: Baseline characteristics were similar between groups. There were also no differences in surgical outcomes, such as operative time, operative bleeding, hospital stay, or complications between groups. The decline rate in AMH was 18.6% (interquartile range (IQR) 2.6-46.8%) in the opportunistic salpingectomy group and 10.4% (IQR 2.6-46.8%) in the no-salpingectomy group, with no significant difference between groups (p = 0.593). Conclusion: Opportunistic salpingectomy at the time of laparoscopic myomectomy was not associated with negative effects on ovarian reserve or increased surgical risk.

Keywords:
Myomectomy, Ovarian reserve, Salpingectomy, Anti-Müllerian hormone, Ovarian cancer
1.
Siegel RL, Miller KD, Jemal A: Cancer statistics, 2015. CA Cancer J Clin 2015;65:5-29.
2.
Erickson BK, Conner MG, Landen CN Jr: The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol 2013;209:409-414.
3.
Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB: Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol 2013;121:14-24.
4.
Anderson CK, Wallace S, Guiahi M, Sheeder J, Behbakht K, Spillman MA: Risk-reducing salpingectomy as preventative strategy for pelvic serous cancer. Int J Gynecol Cancer 2013;23:417-421.
5.
Daly MB, Dresher CW, Yates MS, Jeter JM, Karlan BY, Alberts DS, Lu KH: Salpingectomy as a means to reduce ovarian cancer risk. Cancer Prev Res (Phila) 2015;8:342-348.
6.
Committee on Gynecologic Practice: Committee opinion no. 620: salpingectomy for ovarian cancer prevention. Obstet Gynecol 2015;125:279-281.
7.
Falconer H, Yin L, Gronberg H, Altman D: Ovarian cancer risk after salpingectomy: a nationwide population-based study. J Natl Cancer Inst 2015;107:pii:dju410.
8.
Reade CJ, Finlayson S, McAlpine J, Tone AA, Fung-Kee-Fung M, Ferguson SE: Risk-reducing salpingectomy in Canada: a survey of obstetrician-gynaecologists. J Obstet Gynaecol Can 2013;35:627-634.
9.
Sami Walid M, Heaton RL: The role of laparoscopic myomectomy in the management of uterine fibroids. Curr Opin Obstet Gynecol 2011;23:273-277.
10.
Tone AA, Salvador S, Finlayson SJ, Tinker AV, Kwon JS, Lee CH, Cohen T, Ehlen T, Lee M, Carey MS, Heywood M, Pike J, Hoskins PJ, Stuart GC, Swenerton KD, Huntsman DG, Gilks CB, Miller DM, McAlpine JN: The role of the fallopian tube in ovarian cancer. Clin Adv Hematol Oncol 2012;10:296-306.
11.
Song T, Kim MK, Kim ML, Yoon BS, Seong SJ: Would fewer port numbers in laparoscopy produce better cosmesis? Prospective study. J Minim Invasive Gynecol 2014;21:68-73.
12.
Song T, Kim TJ, Kim WY, Lee SH: Comparison of barbed suture versus traditional suture in laparoendoscopic single-site myomectomy. Eur J Obstet Gynecol Reprod Biol 2015;185:99-102.
13.
Kang JH, Kim WY, Lee KW, Kim KH, Song T: Timing for a laparoscopic myomectomy during the menstrual cycle. J Minim Invasive Gynecol 2015;22:1191-1195.
14.
Song T, Lee SH, Kim WY: Additional benefit of hemostatic sealant in preservation of ovarian reserve during laparoscopic ovarian cystectomy: a multi-center, randomized controlled trial. Hum Reprod 2014;29:1659-1665.
15.
Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 2004;240:205-213.
16.
Findley AD, Siedhoff MT, Hobbs KA, Steege JF, Carey ET, McCall CA, Steiner AZ: Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial. Fertil Steril 2013;100:1704-1708.
17.
Morelli M, Venturella R, Mocciaro R, Di Cello A, Rania E, Lico D, D'Alessandro P, Zullo F: Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol 2013;129:448-451.
18.
Dar P, Sachs GS, Strassburger D, Bukovsky I, Arieli S: Ovarian function before and after salpingectomy in artificial reproductive technology patients. Hum Reprod 2000;15:142-144.
19.
Strandell A, Lindhard A, Waldenstrom U, Thorburn J: Prophylactic salpingectomy does not impair the ovarian response in IVF treatment. Hum Reprod 2001;16:1135-1139.
20.
Gill SE, Mills BB: Physician opinions regarding elective bilateral salpingectomy with hysterectomy and for sterilization. J Minim Invasive Gynecol 2013;20:517-521.
21.
Benaglia L, Somigliana E, Vighi V, Ragni G, Vercellini P, Fedele L: Rate of severe ovarian damage following surgery for endometriomas. Hum Reprod 2010;25:678-682.
22.
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB: A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006;12:685-718.
23.
Esinler I, Bozdag G, Aybar F, Bayar U, Yarali H: Outcome of in vitro fertilization/intracytoplasmic sperm injection after laparoscopic cystectomy for endometriomas. Fertil Steril 2006;85:1730-1735.
24.
Seifer DB, Maclaughlin DT: Mullerian inhibiting substance is an ovarian growth factor of emerging clinical significance. Fertil Steril 2007;88:539-546.
25.
Chang HJ, Han SH, Lee JR, Jee BC, Lee BI, Suh CS, Kim SH: Impact of laparoscopic cystectomy on ovarian reserve: serial changes of serum anti-Müllerian hormone levels. Fertil Steril 2010;94:343-349.
26.
Ferrero S, Venturini PL, Gillott DJ, Remorgida V, Leone Roberti Maggiore U: Hemostasis by bipolar coagulation versus suture after surgical stripping of bilateral ovarian endometriomas: a randomized controlled trial. J Minim Invasive Gynecol 2012;19:722-730.
27.
Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J: Serum anti-Müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323-327.
28.
Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C: Evaluation of anti-Müllerian hormone as a test for the prediction of ovarian reserve. Fertil Steril 2008;90:737-743.
29.
McIlveen M, Skull JD, Ledger WL: Evaluation of the utility of multiple endocrine and ultrasound measures of ovarian reserve in the prediction of cycle cancellation in a high-risk IVF population. Hum Reprod 2007;22:778-785.
30.
Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM: Early follicular serum Müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril 2002;77:468-471.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.